Focus Rheums| Dr. Jekyll or Mr. Hyde? (video)

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

In 2022, Advocacy 101 Returns to Washington, D.C.

  |  

Everyday Expertise

For rheumatologists who may feel they aren’t informed enough to engage in advocacy, Mr. Redinger points to an additional function of the meeting—giving attendees the confidence to engage in advocacy by emphasizing the value of their expertise on rheumatology issues based on their everyday experiences of practicing in the field.

“In the past, Advocacy 101 attendees have become our most involved advocates when it comes to sending messages to their lawmakers, donating to RheumPAC and attending future fly-ins,” he said. “We hope that remains the case for this year’s group going forward.”

ADVERTISEMENT
SCROLL TO CONTINUE

Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis.

Related Articles
    felipe caparros / shutterstock.com

    Copay Accumulator Programs Can Derail Rheumatologic Treatment Plans

    As the medications for rheumatology become more expensive, the need for patient financial assistance becomes paramount. Unfortunately, commercially insured patients are finding it difficult to afford the exorbitant copays required by their plans, and the latest strategy of pharmacy benefit managers (PBMs) threatens to derail rheumatologic treatment goals. High deductible plans combined with copay accumulator…

    A Primer on Copay Accumulator Programs

    The growing use of copay accumulator programs, which restrict the application of patient assistance funds toward cost-sharing requirements, hurts patient access to life-changing treatments. This was one topic discussed during the ACR’s Advocacy Leadership Conference in D.C. this May.